9th February 2015 I Bought 20 shares of JNJ at $99.90 per share plus commission.
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and womens health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSONS, AVEENO, CLEAN & CLEAR, DABAO, JOHNSONS Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names.
This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. (Yahoo Finance)
JNJ is a Dividend Champion with an 52 year streak of dividend increases. Dividend growth rates for 1, 3, 5 and 10 years are 6.6, 7.0, 7.4 and 9.7. (DividendChampions.xls) Johnson & Johnson now pays dividends of $0.70 per share in March, June, September and December.
JNJ's earnings per share has moved nicely upward except a big dip in 2011. After that EPS has continued to grow nicely again.
Some ratings for JNJ:
Yahoo: Mean Recommendation 2.5, 1y Target Est $109.39
Reuters: Mean Rating 2.50
My last purchase 20 shares of JNJ increases €36.88 ($41.72) of expected annual dividend net income, which increases my portfolio projected annual net dividend income to €9064.47. With purchase price $99.90 plus commission my starting yield on cost is 2.80%.
Click here to see my portfolio.
Full Disclosure: Long JNJ